Zepbound Bests Wegovy for Weight Loss in New Trial

WEDNESDAY, Dec. 4, 2024 -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

"Given the increased interest around obesity medications, we conducted...